当前蛋白身份:P21554 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1LVQ IC3 of CB1 Bound to G(alpha)i 提交 2002-05-29 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 338–346(9 aa) 片段:IC3 of CB1 (residues 338-346)
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6;303 K;离子强度(mmCIF原始值)10 mM acetate;压力 1
NMR样品组成 LAKT peptide at 4.0 mM, G(alpha)i at 200 uM. | 10 mM acetate buffer, pH 6.0, 1 mM DTT, TSP
分辨率未提供
1LVR IC3 of CB1 (L431A,A432L) Bound to G(alpha)i 提交 2002-05-29 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 338–346(9 aa) 片段:IC3 of CB1(residues 338-346)
突变:L4A,A5L 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6;308 K;离子强度(mmCIF原始值)10 mM acetate buffer;压力 1
NMR样品组成 ALKT 4.0 mM G(alpha)i 200 uM | acetate buffer, 10 mM
分辨率未提供
23IV Cannabinoid Receptor 1-Gi Complex 提交 2026-02-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 D 1–472(472 aa)
未记录 A1E5S methyl 1-[[1-[(4-fluorophenyl)methyl]indazol-3-yl]carbonylamino]cyclopropane-1-carboxylate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.42 Å
23IW Cannabinoid Receptor 1-Gi Complex 提交 2026-02-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 1–472(472 aa)
未记录 A1E5T methyl (2~{S},3~{R})-2-[[1-[(4-fluorophenyl)methyl]indazol-3-yl]carbonylamino]-3-oxidanyl-butanoate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.42 Å
2B0Y Solution Structure of a peptide mimetic of the fourth cytoplasmic loop of the G-protein coupled CB1 cannabinoid receptor 提交 2005-09-15 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 400–416(17 aa) 片段:Fragment of the C-terminal juxtramembrane region of CB1 Cannabinoid receptor(Intracellular 4th loop region CB1 401-417)
突变:C16S 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 3;310 K;离子强度(mmCIF原始值)no salts used;压力 ambient
NMR样品组成 5 mM sample in H2O (9:1 H2O/2H2O, pH 3.0). | 70 mM SDS
分辨率未提供
2KOE Human cannabinoid receptor 1 - helix 7/8 peptide 提交 2009-09-18 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 377–416(40 aa)
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 310 K;压力 ambient
NMR样品组成 1 mM peptide, 30 % TFE, 95% H2O/5% D2O | 95% H2O/5% D2O
分辨率未提供
5TGZ Crystal Structure of the Human Cannabinoid Receptor CB1 提交 2016-09-28 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 99–306(208 aa) 片段:UNP RESIDUES 99-306,UNP RESIDUES 2-148,UNP RESIDUES 332-414
链 A 332–414(83 aa) 片段:UNP RESIDUES 99-306,UNP RESIDUES 2-148,UNP RESIDUES 332-414
突变:T210A, E273K, T283V,P1002A, Y1098W,R340E 突变:T210A, E273K, T283V,P1002A, Y1098W,R340E ZDG 4-[4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin-1-ylcarbamoyl)pyrazol-3-yl]phenyl]but-3-ynyl nitrate × 1 FMN FLAVIN MONONUCLEOTIDE × 1 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1 OLA OLEIC ACID × 3 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;293 K;0.1M HEPES pH 7.0-7.4, 100mM (NH4)2HPO4, 25%-32% PEG 400, 2-20 mM Ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA)
分辨率 2.80 Å R-free 0.238
5U09 High-resolution crystal structure of the human CB1 cannabinoid receptor 提交 2016-11-23 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 90–301(212 aa) 片段:P21554 residues 90-301, 333-421 and Q9V2J8 residues 218-413
链 A 333–421(89 aa) 片段:P21554 residues 90-301, 333-421 and Q9V2J8 residues 218-413
突变:T210A 突变:T210A PEG DI(HYDROXYETHYL)ETHER × 9 SO4 SULFATE ION × 4 7DY N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 5.5;293 K;31% PEG400, 100mM Sodium Citrate pH5.5, 100mM magnesium sulfate
分辨率 2.60 Å R-free 0.238
5XR8 Crystal structure of the human CB1 in complex with agonist AM841 提交 2017-06-07 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 99–306(208 aa) 片段:;UNP residues 99-306,UNP residues 3-148,UNP residues 332-414,UNP residues 99-306,UNP residues 3-148,UNP residues 332-414,UNP residues 99-306,UNP residues 3-148,UNP residues 332-414 ;
链 A 332–414(83 aa) 片段:;UNP residues 99-306,UNP residues 3-148,UNP residues 332-414,UNP residues 99-306,UNP residues 3-148,UNP residues 332-414,UNP residues 99-306,UNP residues 3-148,UNP residues 332-414 ;
突变:T210A,E273K,T283V,Y1098W,R340E 突变:T210A,E273K,T283V,Y1098W,R340E FMN FLAVIN MONONUCLEOTIDE × 1 8D0 (6~{a}~{R},9~{R},10~{a}~{R})-9-(hydroxymethyl)-3-(8-isothiocyanato-2-methyl-octan-2-yl)-6,6-dimethyl-6~{a},7,8,9,10,10~{a}-hexahydrobenzo[c]chromen-1-ol × 1 CLR CHOLESTEROL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 6.2;293 K;0.1 M sodium cacodylate trihydrate pH 6.2, 120 mM C6H5Na3O7, 30% PEG400 and 100 mM Glycine
分辨率 2.95 Å R-free 0.274
5XRA Crystal structure of the human CB1 in complex with agonist AM11542 提交 2017-06-08 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 99–306(208 aa) 片段:UNP residues 99-306,UNP residues 3-148,UNP residues 332-414
链 A 332–414(83 aa) 片段:UNP residues 99-306,UNP residues 3-148,UNP residues 332-414
突变:T210A, E273K, T283V,Y1098W,R340E 突变:T210A, E273K, T283V,Y1098W,R340E FMN FLAVIN MONONUCLEOTIDE × 1 8D3 (6aR,10aR)-3-(8-bromanyl-2-methyl-octan-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol × 1 OLA OLEIC ACID × 2 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2 PEG DI(HYDROXYETHYL)ETHER × 1 CLR CHOLESTEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;293 K;0.1 M sodium cacodylate trihydrate pH 6.4, 300-350 mM C4H4KNaO6, 30% PEG400
分辨率 2.80 Å R-free 0.252
6KPG Cryo-EM structure of CB1-G protein complex 提交 2019-08-15 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 71–425(355 aa)
突变:E273K, T283V, R340E 8D0 (6~{a}~{R},9~{R},10~{a}~{R})-9-(hydroxymethyl)-3-(8-isothiocyanato-2-methyl-octan-2-yl)-6,6-dimethyl-6~{a},7,8,9,10,10~{a}-hexahydrobenzo[c]chromen-1-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.00 Å
6KQI Structure of an allosteric modulator bound to the CB1 cannabinoid receptor 提交 2019-08-17 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 94–301(208 aa) 片段:C1
链 A 333–413(81 aa) 片段:C1
突变:S203K,T210A,E273K,T283V,R340E 突变:S203K,T210A,E273K,T283V,R340E 9GF 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol × 1 9GL 5-chloro-3-ethyl-N-{2-[4-(piperidin-1-yl)phenyl]ethyl}-1H-indole-2-carboxamide × 1 OLA OLEIC ACID × 4 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2 PEG DI(HYDROXYETHYL)ETHER × 2 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 6;293 K;33% PEG 400, 100mM Sodium Cacodylate pH 6.0, 100mM Sodium Malonate
分辨率 3.25 Å R-free 0.312
6N4B Cannabinoid Receptor 1-G Protein Complex 提交 2018-11-18 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 1–472(472 aa)
未记录 KCA methyl N-{1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}-3-methyl-L-valinate × 1 CLR CHOLESTEROL × 2 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.00 Å
7FEE Crystal structure of the allosteric modulator ZCZ011 binding to CP55940-bound cannabinoid receptor 1 提交 2021-07-19 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 74–89(16 aa)
链 A 90–305(216 aa)
链 A 333–414(82 aa)
突变:S203K,T210A,E273K,T283V,R340E,N393D 突变:S203K,T210A,E273K,T283V,R340E,N393D 突变:S203K,T210A,E273K,T283V,R340E,N393D CLR CHOLESTEROL × 2 9GF 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol × 1 7IC 6-methyl-3-[(1S)-2-nitro-1-thiophen-2-yl-ethyl]-2-phenyl-1H-indole × 1 PEG DI(HYDROXYETHYL)ETHER × 2 GOL GLYCEROL × 4 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2 OLA OLEIC ACID × 4 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 6;293 K;25-36% PEG 300, 100Mm MES pH 6.0, 120-190mM Magnesium Sulfate
分辨率 2.70 Å R-free 0.319
7V3Z Structure of cannabinoid receptor type 1(CB1) 提交 2021-08-12 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 102–306(205 aa)
链 A 336–414(79 aa)
突变:H154L,T210A,E273K,T283V,Y1098W,R340E 突变:H154L,T210A,E273K,T283V,Y1098W,R340E 9GF 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol × 1 CLR CHOLESTEROL × 1 FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 LIPIDIC CUBIC PHASE;pH 7.2;293.15 K;30% PEG400, 100 mM HEPES sodium pH 7.2, 80-100mM sodium citrate tribasic dihydrate
分辨率 3.29 Å R-free 0.276
7WV9 Allosteric modulator ZCZ011 binding to CP55940-bound cannabinoid receptor 1 in complex with Gi protein 提交 2022-02-10 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 1–472(472 aa)
未记录 9GF 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol × 1 7IC 6-methyl-3-[(1S)-2-nitro-1-thiophen-2-yl-ethyl]-2-phenyl-1H-indole × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.36 Å
8GAG Cannabinoid receptor 1-Gi complex with novel ligand 提交 2023-02-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 1–472(472 aa)
未记录 YVF methyl (2R)-2-({(1M)-5-methyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonyl}amino)-2-(thiophen-2-yl)propanoate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.30 Å
8GHV Cannabinoid Receptor 1-G Protein Complex 提交 2023-03-12 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 D 1–472(472 aa)
未记录 ZI5 (5Z,8Z,11Z,13S,14Z)-N-[(2R)-1-hydroxypropan-2-yl]-13-methylicosa-5,8,11,14-tetraenamide × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.80 Å
8IKG Cryo-EM structure of human receptor with G proteins 提交 2023-02-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 99–408(310 aa)
未记录 Q2B 3-[(1S)-1-(furan-2-yl)-2-nitro-ethyl]-2-phenyl-1H-indole × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.40 Å
8IKH Cryo-EM structure of human receptor with G proteins 提交 2023-02-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 99–408(310 aa)
未记录 Q2L 3-[(1R)-1-(2-methoxyphenyl)-2-nitro-ethyl]-2-phenyl-1H-indole × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.30 Å
8K8J Cannabinoid Receptor 1 bound to Fenofibrate coupling MiniGsq and Nb35 Complex 提交 2023-07-30 Assembly 1 信息不足 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 71–425(355 aa)
未记录 J3O Fenofibrate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.88 Å
8WRZ Cry-EM structure of cannabinoid receptor-beta-arrestin-1 complex 提交 2023-10-16 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 R 71–432(362 aa)
突变:M29W, H124I, T210I, E273K, T283V, R340E 8D0 (6~{a}~{R},9~{R},10~{a}~{R})-9-(hydroxymethyl)-3-(8-isothiocyanato-2-methyl-octan-2-yl)-6,6-dimethyl-6~{a},7,8,9,10,10~{a}-hexahydrobenzo[c]chromen-1-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.60 Å
8WU1 Cryo-EM structure of CB1-beta-arrestin1 complex 提交 2023-10-19 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 R 1–413(413 aa)
非标准单体:是(mmCIF未提供具体位点) KCA methyl N-{1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}-3-methyl-L-valinate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.20 Å
9B54 Biased agonist bound CB1-Gi structure 提交 2024-03-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 1–472(472 aa)
未记录 A1AIW methyl N-{6-(4-carbamimidamidobutoxy)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}-3-methyl-L-valinate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.86 Å
9B65 Biased agonist bound CB1-Gi structure 提交 2024-03-23 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 1–472(472 aa)
未记录 KCA methyl N-{1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}-3-methyl-L-valinate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.03 Å
9B9Y Structural mechanism of CB1R binding to peripheral and biased inverse agonists 提交 2024-04-03 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 R 96–301(206 aa)
链 R 333–416(84 aa)
未记录 7DY N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.50 Å
9B9Z Structural mechanism of CB1R binding to peripheral and biased inverse agonists 提交 2024-04-03 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 R 96–301(206 aa)
链 R 333–416(84 aa)
未记录 A1AKO (4S)-3-(4-chlorophenyl)-N'-[(1E)-ethanimidoyl]-4-phenyl-N-[4-(trifluoromethyl)benzene-1-sulfonyl]-4,5-dihydro-1H-pyrazole-1-carboximidamide × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.30 Å
9BA0 Structural mechanism of CB1R binding to peripheral and biased inverse agonists 提交 2024-04-03 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 R 96–301(206 aa)
链 R 333–416(84 aa)
未记录 A1AKN N-(N-{(E)-[(4S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl][4-(trifluoromethyl)benzene-1-sulfonamido]methylidene}carbamimidoyl)acetamide × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.13 Å
9DGI Cannabinoid receptor 1-Gi complex with novel ligand 提交 2024-09-02 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 R 1–472(472 aa)
未记录 YVF methyl (2R)-2-({(1M)-5-methyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonyl}amino)-2-(thiophen-2-yl)propanoate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.35 Å
9EGO Cannabinoid receptor 1-Gi complex with novel ligand 提交 2024-11-21 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 1–472(472 aa)
未记录 YVF methyl (2R)-2-({(1M)-5-methyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonyl}amino)-2-(thiophen-2-yl)propanoate × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.20 Å
9ERX Structural basis of D9-THC analog activity at the Cannabinoid 1 receptor 提交 2024-03-25 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 R 2–472(471 aa)
未记录 A1H66 (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.90 Å